Clinical trials for both CLBP and CHF have not been run in Japan. As for Remestemcel-L - Temcell , I belive JCR have developement rights.
Cell Therapy News/Articles, page-15049
-
- There are more pages in this discussion • 3,380 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.28 |
Change
0.003(0.20%) |
Mkt cap ! $1.467B | |||
| Open | High | Low | Value | Volume |
| $1.29 | $1.31 | $1.27 | $1.029M | 801.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 27551 | $1.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 55728 | 13 |
View Market Depth
| Last trade - 14.11pm 05/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |